Neonc Technologies Holdings, Inc. · NASDAQ:NTHI
Neonc Technologies — Investor Presentation (January 2026)
37 slides from Neonc Technologies's investor presentation, January 2026
Slide 1: Removing Barriers to Effective Neuro-Drug Delivery
NTHI Removing Barriers to Effective Neuro-Drug Delivery Corporate Presen ta tio n 2025
Slide 2: Important Cautions Regarding Forward Looking Statements
Important Cautions Regarding Forward Looking Statements This document does not constitute or form part of an invitation or We have based the forward-looking statements on our current expectations and recommendation to subscribe for or purchase any securities. The distribution projections about futur
Slide 3: Executive Summary
Executive Summary Founded in 2023, NTHI is a Our platform is designed to Robust IP Portfolio NTHI first mover advantage clinical stage life sciences enable the creation of company. breakthrough drug candidates Holds 179 biotech-related patents Innovative intranasal CNS drug delivery, and cutting-edg
Slide 4: Board of Directors
Board of Directors Victoria Medvec, PhD Bader Al Monawer Jim Delshad Compensation Committee Chair Steven L Giannotta, MD Alan Chiang, MD, PhD. MBA, FICS Audit Committee Chair Corporate Governance Chair 20+ years as CEO of Medvec & More than a decade of Chair Emeritus of Served two terms as Mayor Boa
Slide 5: Senior Management Team
Senior Management Team Our management team possesses significant experience in capital markets, with a track record of building shareholder value in clinical biotech companies. Amir F. Heshmatpour Thomas Chen, MD, Ph.D. Josh Neman , PhD Keithly A. Garnett CEO, Executive Chairman & President Founder,
Slide 6: Scientific Advisory Board
Scientific Advisory Board Our Scientific Advisory Board provides objective perspective and guidance in product development, clinical trials, regulatory compliance, and biotech commercialization strategies. David M. Ashley, MBBS (Hons), Henry S. Friedman, MD Axel H. Schönthal, PhD Alan Chiang, MD, Ph
Slide 7: Key Takeaways: Integrated GCC/MENA Platform
Key Takeaways • Integrated GCC/MENA Platform – NuroMENA (controlled by Quazar Investment) and NuroCure (controlled by NuroMENA) hold the exclusive sub- license for all 178 NTHI patents in the GCC and MENA. NTHI retains 20% non-dilutive equity and negative control rights over Board and management. •
Slide 8: NeOnc's Game-Changing Acquisition from McMaster University & USC
NeOnc’s Game-Changing Acquisition from McMaster University & USC Acquisition of SilicoVitro Technology • Strengthens NeOnc’s leadership in next-generation CNS cancer research with SilicoVitro’s AI engine and patented 3D bioprinting platform (US Patent No. 11,788,057 B2) • Accelerates clinical progra
Slide 9: Phase 2 Development & Clinical Pipeline
Phase 2 Development & Clinical Pipeline Important Disclaimer: This development & clinical pipeline is subject to regulatory approval, risk and uncertainties, as well as potential changes to the pipeline and other factors that are beyond our control. FDA Authorized Clinical Trials Drug IND Applicatio
Slide 10: Sites in pre-activation phase
Sites in pre-activation phase Tufts Medicine Penn State Washington University Johns Hopkins Harvard/ Mass General Hospital New York University Tampa General University of South Carolina Washington University Northwestern University Beverly Hills Cancer Center Pacific Neuroscience Institute Sutter He
Slide 11: The Need
The Need 1 Million 29% #1 American Adults are of Brain Tumors are Brain Tumors are the Living with a Primary Malignant (Cancerous) Leading Cause Of Cancer- Brain Tumor Related Death Among Children 13,657 are Children 94,390 18,990 1-in-143 New Primary Brain Tumors Patients Expected to Lose Your Odds
Slide 12: The Challenge
The Challenge While the FDA has approved many drugs for treating Malignant Glioblastomas (GBM), survival rates remain low with no significant improvem ent in prognosis over past 50 years. Lack of Progress Primarily Due to Natural Resistance Mechanisms that Limit Efficacy of GBM Treatments Therapeuti
Slide 13: Our Strategic Focus: Deliver Intranasal Chemotherapy to Bypass the Blood-Brain Barrier
Our Strategic Focus: Deliver Intranasal Chemotherapy to Bypass the Blood-Brain Barrier and Directly Target Brain Tumors •Direct Brain Access: Intranasal delivery is designed to enable small-molecule therapeutics to bypass the BBB via the olfactory and trigeminal nerves, reaching the brain through th
Slide 14: NEO100: Foundation of a Next-Generation Drug Delivery Platform
NEO100: Foundation of a Next- Generation Drug Delivery Platform • NEO100 Platform: NEO100 is our first drug candidate and the foundation of our NEO platform, aimed at creating novel therapeutics and delivery methods. • Proprietary Chemistry: NEO100 is a patented, ultra-pure pharmaceutical compound d
Slide 15: NEO100 Offers Broad Potential for Clinical Benefit and Commercial Application
NEO100 Offers Broad Potential for Clinical Benefit and Commercial Application Designed to act as a When delivered intranasally, When delivered intra-arterially, regulator its small molecular size is it may create a temporary opening for neurologic pathways designed to allow it to bypass in the BBB,
Slide 16: With three mechanisms of action, NEO100 is designed to combat tumors
With three mechanisms of action, NEO100 is designed to corner and combat tumors from all sides. NEO100 1 3 2 Cytoplasmic RAS Oncoprotein Na/K-ATPase Membrane Inhibition Inhibition Disruption Electrolyte Imbalance (Na+, K+, Ca++) Endoplasmic Reticulum Stress (Unfolded Protein Response) Cell Cycle Arr
Slide 17: NEO212: Our First Drug Conjugate and Second Product Candidate
NEO212: Our First Drug Conjugate and Second Product Candidate Background Purpose • Efficient BBB Penetration: NEO212 Bioconjugated Molecule • A novel hybrid molecule Designed to cross the blood-brain combining NEO100 with the FDA-approved barrier more effectively for targeted chemotherapeutic agent
Slide 18: NEO212 Mechanism of Action
NEO212 Mechanism of Action Chen TC et al. Cancer Lett. 2015 Mar 28;358(2):144-151. Cho HY et al. Neurooncol Adv. 2020 Nov 20;2(1):vdaa160. Cho HY et al Mol Cancer Ther. 2014 Aug;13(8):2004-17. 18
Slide 19: Focused on delivery aligned with rapidly expanding global market opportunities
We are focused on delivery of therapeutic innovations aligned with rapidly expanding global market opportunities. Global Market Outlook & Drivers CNS Treatment Market Brain Tumor Drug Market Global, USD Billions 1 Global, USD Billions 2 • Global CNS treatment market is projected to grow at a 8.6% CA
Slide 20: Our Expanding IP Portfolio of Global Patents Creates Competitive Advantages
Our Expanding IP Portfolio of Global Patents Creates Competitive Advantages NEO is a First-of-its-kind Platform Composition & Method Claims Issued & Pending Patent Applications Protected By Patents in the U.S., Canada, NEO100 Ultrapure POH – Issued patents expiring China, UK & EU U.S. Patents in 203
Slide 21: NEO100 Phase I Clinical Trial Results
NEO100 Phase I Clinical Trial Results Initiated: April 2017 Protocol Length: 2 years • Patients were divided into four groups and given Size: 12 patients varying dosages of NEO-100 intranasally four times a day (384 mg, 576 mg, 768 mg, 1152 mg) Locations: Cleveland Clinic; University of Washington/S
Slide 22: NEO100 Phase I Survival Data
NEO100 Phase I Survival Data NEO100 OVERALL SURVIVAL RATES NEO100 TREATMENT CYCLE NEO100 TREATMENT OF SURVIVAL RATES PATIENTS WITH IDH1 MARKER Survival Survival Survival % OS12 MEDIAN OS24 % % 55% OS 37% COMPLETED HAS IDH1 MORE THAN MUTATIONS 5 TREATMENT CYCLES COMPLETED LESS THAN 5 TREATMENT NO IDH
Slide 23: Before & After NEO100 Treatment
Before & After NEO100 Treatment January 2023 October 2023 Brain Scan Shows Significant Tumor Reduction at Nine Months Following Treatment with NEO100 23
Slide 24: NEO100 Phase I Survival Rate vs. Standard of Care
NEO100 Phase I Survival Rate vs. Standard of Care for Recurrent High-grade Gliomas NEO 100 Phase I SURVIVAL Comparison of Overall Patient Survival of Recurrent GBM Patients per Treatment vs. Standard of Care Method Shown here are Kaplan-Meier curves representing OS-12 the probability of survival of
Slide 25: What Sets Us Apart
What Sets Us Apart NEO100 vs. Current Standard of Care for Recurrent High-Grade Gliomas vs. Current Standard of Care for Recurrent High-Grade Gliomas Repeat Oral Bevacizumab Gamma Gliadel Novocure Surgery Lomustine (Avastin) Tiles Wafers No Surgery Required 1 - - - Bone Marrow Unaffected
Slide 26: NEO100 Phase II Clinical Trial Underway
NEO100 Phase II Clinical Trial Underway Expect Phase II to provide the data needed to advance NEO100 toward commercialization. Purpose: Determine the impact of NEO100 Rationale: IDH1 mutant tumor Phase II Clinical Trial Affinity Sites inhalation therapy on a sample group that has patients in the tri
Slide 27: NEO100-01 Phase 2a: 6-Month Progression Free Survival
NEO100-01 Phase 2a: 6-Month Progression Free Survival Historical Metric NEO100-01 IDH1 mut recurrent HGG1,2 6 months Progression 44% (8/18) 21-31% Free Survival ≥6-month follow-up prior to data cutoff. References: 1 Fanucci et al., 2023 2 Walbert et al. 2010
Slide 28: Breakthrough Intranasal NEO100: Tumor Regression and Long-Term Survival
Breakthrough Intranasal NEO100: Tumor Regression and Long- Term Survival in High-Grade IDH1-Mutant Astrocytoma Primary Study long term survivor, Cycles Time on NEO100 Long Term Patient ID Sex Age as of 10/4/2025 WHO Diagnosis Diagnosis C1D1 Date Alive Phase radiographic response, both Completed (yea
Slide 29: Long-Term Survival: Recurrent WHO Grade 3/4 IDH1-mutant Astrocytoma
Long-Term Survival: Recurrent WHO Grade 3/4 IDH1-mutant Astrocytoma • 9 of 25 patients are long-term survivors, surviving ≥18 months following initiation of NEO100, with a median overall survival of 88 months • No major toxicity reported across cohort; chronic intranasal dosing well tolerated • Adve
Slide 30: Summary: NEO100-01 Clinical Outcomes
Summary: NEO100-01 Clinical Outcomes for Recurrent WHO Grade 3/4 IDH1-mutant Astrocytoma Progression-Free Survival: 44% of patients achieved 6-month progression-free survival (PFS-6), outperforming historical benchmarks of 21–31% for IDH1- mutant recurrent high-grade gliomas. Radiographic Response:
Slide 31: NEO100: Impact & Significance
NEO100: Impact & Significance • First-of-its-kind signal for durable response: MRI- confirmed significant response in setting rarely seen • Potential paradigm shift with multi-year survival: CNS-penetrant metabolic therapy • Differentiation: Minimal toxicity vs. standard salvage therapies • Translat
Slide 32: NEO212 Clinical Trials
NEO212 Clinical Trials Received FDA Investigational New Phase I (Now Underway) Phase I Trial Elements: Drug (IND) approval to initiate Phase Main objective to assess the safety and Comparison of NEO212 to I/II clinical trials of NEO212 preliminary efficacy of NEO212 in temozolomide (TMZ). administer
Slide 33: Pediatric Brain Cancer
Pediatric Brain Cancer The Need The Challenge Our Solution Radiation & chemotherapy for ▪ NEO100: our first therapeutic being Brain Tumors are the Leading children with high-grade developed for pediatric patients #1 Cause of Cancer-Related Death Among Children. gliomas are: diagnosed with pHGGS. Com
Slide 34: Pediatric Indication Next Steps
Pediatric Indication Next Steps California Institute for Regenerative Pediatric Neuro-oncology Consortium Medicine (CIRM) Application (PNOC) Enrollment • Recruit clinical sites for study to include: • Initiate Phase I Clinical Trial • Apply for CIRM grant. • Conduct clinical trial with PNOC. Rare Di
Slide 35: Future CNS Treatment Possibilities
Future CNS Treatment Possibilities Possibilities to Explore Following Commercial Launch of Our NEO100 & NEO212 for Brain Cancer Parkinson's Alzheimer's Bipolar Disorder Epilepsy Migraines Brain Metastases Autoimmune Spinal Cord Disease Injury By Enabling Greater Penetration of the BBB, We Believe ou
Slide 36: NTHI: Key Takeaways
NTHI: Key Takeaways • First-Mover Advantage: Pioneering non-invasive intranasal drug delivery for central nervous system (CNS) diseases • Robust IP Protection: Backed by a global portfolio of 179 patents • Near-Term Milestones: Clinical trials nearing full enrollment with upcoming data readouts • Gl
Slide 37: Contact Us
Contact Us Company Contact NeOnc Technologies Holdings, Inc. 23975 Park Sorrento, Suite 205 Calabasas, CA 91302 Tel +1 (818) 470-NTHI Info@neonc.com www.neonc.com Investor Relations Hayden IR 2369 Lexington Avenue, Second Floor New York, New York 10017 Brett Maas Managing Partner brett@haydenir.com
NeOnc Technologies Holdings — Investor Presentation (January 2026) on 6ix